<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100725004443N30</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-25</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of comprehensive tele-empowerment program on self-care, uncertainty and readmission in patients with heart failure</public_title>
      <acronym></acronym>
      <scientific_title>The effect of comprehensive tele-empowerment program on self-care behaviours, uncertainty and readmission in patients with heart failure</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61895</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The samples will be selected by continuous sampling and the patients will be placed in two groups of control and case by Block Balanced Randomization (BBR). By using the free website http://www.randomization.com/, the assignment sequence will take place. In such a way that the number of subjects in each block will be set to 4, for the control group letter A and for the case group, the letter B will be considered, and finally, by approving the Randomization Sequence in the system for 24  blocks, The assignment sequence will be created for the 96 samples by combining the letters A and B. Finally, the cards containing the blocks will be placed inside the standard envelope, and as a result, allocation concealment will be considered and observed. Based on qualified samples, a Shuffling Envelope will be taken by the researcher accidentally. Finally, the random allocation method will be determined by the research samples.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Patients with heart failure.</hc_freetext>
      <i_freetext>Intervention 1: Control group: These patients do not receive any intervention from the researcher, and after the initial visit by the physician, patients will be provided with routine care in heart failure. Intervention 2: Intervention group: Patients in the intervention group will receive 10 weeks of intervention, including 6 weeks of comprehensive tele-empowerment program and 4 weeks of follow-up. Initially, patients will join virtual groups of 10 to 15 people, and the empowerment program will be done comprehensively and according to the physical, psychological and spiritual needs of patients; through the Internet and on the electronic massaging platform. Each week, a specific topic will be addressed to promote patients' self-care. Topics will include familiarity with heart failure and clinical manifestations monitoring, diet modification, physical activity improvement, drug management, stress management and relaxation techniques, spiritual self-awareness and religious coping strategies. The content of each session will be available to all patients equally for 6 weeks as a combination of online and offline sessions (3 online sessions and 3 offline sessions).In offline sessions, an e-booklet and/or an instructional video will be sent to virtual groups, and in online sessions, a Skyroom link will be placed in the virtual group to hold online group sessions. Online group meetings with members of groups of 10 to 15 people formed on the social network will be held for 45 to 60 minutes via the Skyroom platform. This empowerment program will include 5 steps entitled 1) Needs Assessment 2) Goal Setting 3) Structured Education  4) Self-Care Plan Development 5) Evaluation which all steps will be repeated by the researcher and through the electronic messaging program for all the mentioned sessions for each week. Finally, over the next four weeks, patients will be followed up by a 10-minute phone call and their questions will be answered.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The collected deidentified IPD including demographic information, medical history, study outcomes, and other relevant variables

When:
Data will be available 6 months after publication of the study results up to a period of 5 years after the end of the study.

To whom:
The deidentified IPD and supporting information will be made available to qualified researchers upon reasonable request.

Conditions:
Access to the data will be granted to qualified researchers and for research purposes only. Researchers must be affiliated with an academic or research institution and provide the approved proposal and evidence of their qualifications, such as a curriculum vitae or publication record. Requests will be reviewed by the corresponding author to ensure that they are consistent with the study's original aims and objectives.

Where to obtain:
To obtain the deidentified IPD, interested researchers should submit a request to the corresponding author by email.

How to obtain:
To request access to the deidentified IPD, interested researchers should submit a request to the corresponding author including a detailed research plan that outlines the research question(s) being addressed, the specific data being requested, and the analytic methods to be used. Researchers should also provide the approved proposal and also evidence of their qualifications and data protection plans.
 Requests will be reviewed by the corresponding author to ensure that they are consistent with the study's original aims and objectives. Upon receipt of a request, the corresponding author will review the request and respond within 10 business days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Khanipour-Kencha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery School of Tehran University, Easte Nosrat St., Tohid Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6105 4000</telephone>
        <email>ali.khanipour76@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Masoumeh Zakerimoghadam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and Midwifery School of Tehran University, Easte Nosrat St., Tohid Square, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6105 4000</telephone>
        <email>mzakerimo@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Medical diagnosis of class II or III heart failure (according to the New York Heart Association [NYHA] classification) based on the patient's medical record
Medical diagnosis of heart failure for at least 3 months
Ability to read and write Persian language
Access and ability to use smart phones and the Internet
Willingness to participate and complete intervention sessions, social media group interactions, and data collection measures</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diagnosed mental and cognitive disorders documented in the medical record
Having vision, hearing, or speaking deficits
Participation in or experience of joining similar empowerment programs
Heart failure exacerbation
reporting experience of severe psychological distress during the study period.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Heart failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: These patients do not receive any intervention from the researcher, and after the initial visit by the physician, patients will be provided with routine care in heart failure.</i_keyword>
      <i_keyword>Intervention group: Patients in the intervention group will receive 10 weeks of intervention, including 6 weeks of comprehensive tele-empowerment program and 4 weeks of follow-up. Initially, patients will join virtual groups of 10 to 15 people, and the empowerment program will be done comprehensively and according to the physical, psychological and spiritual needs of patients; through the Internet and on the electronic massaging platform. Each week, a specific topic will be addressed to promote patients' self-care. Topics will include familiarity with heart failure and clinical manifestations monitoring, diet modification, physical activity improvement, drug management, stress management and relaxation techniques, spiritual self-awareness and religious coping strategies. The content of each session will be available to all patients equally for 6 weeks as a combination of online and offline sessions (3 online sessions and 3 offline sessions).In offline sessions, an e-booklet and/or an instructional video will be sent to virtual groups, and in online sessions, a Skyroom link will be placed in the virtual group to hold online group sessions. Online group meetings with members of groups of 10 to 15 people formed on the social network will be held for 45 to 60 minutes via the Skyroom platform. This empowerment program will include 5 steps entitled 1) Needs Assessment 2) Goal Setting 3) Structured Education  4) Self-Care Plan Development 5) Evaluation which all steps will be repeated by the researcher and through the electronic messaging program for all the mentioned sessions for each week. Finally, over the next four weeks, patients will be followed up by a 10-minute phone call and their questions will be answered.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Self-care behaviors. Timepoint: Before the intervention, immediately after ending the intervention. Method of measurement: Nine-Item European Heart Failure Self-Care Behavior Scale (EHFScBS-9).</prim_outcome>
      <prim_outcome>Uncertainty. Timepoint: Before the intervention, immediately after ending the intervention. Method of measurement: Mishel Uncertainty in Illness Scale - Community form (MUIS-C).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number and duration of emergency hospital readmission of patients. Timepoint: Immediately after ending the intervention. Method of measurement: Self-Report of Patients.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-09</approval_date>
        <contact_name>Research Ethics Committee of the School of Nursing and Midwifery, Tehran University of Medical Scien</contact_name>
        <contact_address>Room 604, Sixth Floor, Office building of Tehran University of medical Sciences, Intersection of Ghods St., Keshavarz Blvd., Tehran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
